• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by UnitedHealth Group Incorporated

    11/13/25 6:07:17 AM ET
    $UNH
    Medical Specialities
    Health Care
    Get the next $UNH alert in real time by email
    S-8 1 forms-8.htm S-8

     

    As filed with the Securities and Exchange Commission on November 13, 2025

     

    Registration No. 333-                 

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

     

    FORM S-8 

    REGISTRATION STATEMENT

    UNDER

    THE SECURITIES ACT OF 1933

     

     

     

    UnitedHealth Group Incorporated

    (Exact name of registrant as specified in its charter)

     

     

     

    Delaware   41-1321939
    (State or other jurisdiction of
    incorporation or organization)
     

    (I.R.S. Employer

    Identification Number)

     

    1 Health Drive

    Eden Prairie, Minnesota 55344

      655 New York Avenue NW
    Washington, DC 20001
    (Address of Principal Executive Offices) (Zip Code)   (Address of Principal Executive Offices) (Zip Code)

     

    BIND BENEFITS, INC. 2017 EQUITY INCENTIVE PLAN

    (Full title of the plans)

     

    Christopher R. Zaetta

    Executive Vice President and Chief Legal Officer

     

    1 Health Drive

    Eden Prairie, Minnesota 55344

      655 New York Avenue NW
    Washington, DC 20001

     

    (Name and address of agent for service)

    (800) 328-5979(Telephone number, including area code, of agent for service)

     

     

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer ☒ Accelerated filer ☐
           
    Non-accelerated filer ☐ (Do not check if a smaller reporting company) Smaller reporting company ☐
           
        Emerging growth company ☐

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act.  ☐

     

     

     

     

      

     

    EXPLANATORY NOTE

     

    UnitedHealth Group Incorporated (the “Company” or the “registrant”) has filed this registration statement on Form S-8 to register 655,608 shares of Company common stock, $0.01 par value per share (the “Common Stock”), issuable upon the exercise of outstanding stock options issued under the Bind Benefits, Inc. 2017 Equity Incentive Plan (the “2017 Plan”). On November 12, 2025 (the “Effective Time”), the Company’s wholly-owned subsidiary UnitedHealthcare Services, Inc. (“UHS”) purchased substantially all of the outstanding stockholder equity in Bind Benefits, Inc. that was not owned previously by UHS or an indirect wholly owned subsidiary of the Company pursuant to the exercise of the Put Option under Bind Benefits, Inc.’s Amended and Restated Right of First Refusal and Co-Sale Agreement, dated October 20, 2020 (as amended). At the Effective Time, certain outstanding stock options to purchase shares of Bind Benefits, Inc. common stock under the 2017 Plan (the “Bind Options”) were assumed by the Company and converted into stock options to purchase shares of Common Stock.

     

    The registered shares represent the maximum number of shares of Company Common Stock issuable upon the vesting, settlement or exercise of the Bind Options, subject to appropriate adjustments thereto.

     

    Conversion of Stock Options of Bind Benefits, Inc.

     

    At the Effective Time, each outstanding Bind Option, whether vested or unvested immediately prior to the Effective Time, was converted into an option to purchase a number of shares of Company Common Stock equal to the product (rounded down to the nearest whole number) of the total number of shares of Bind common stock subject to such Bind Option immediately prior to the Effective Time times the Equity Award Exchange Ratio (as defined below) at an exercise price per share (rounded up to the nearest whole cent) equal to the exercise price per share of Bind common stock subject to such Bind Option immediately prior to the Effective Time divided by the Equity Award Exchange Ratio. The “Equity Award Exchange Ratio” means (i) the price per share of Bind common stock determined in connection with the exercise of the Put Option divided by (ii) the closing sale price per share of Company Common Stock on the New York Stock Exchange, as reported in the New York City edition of The Wall Street Journal (or, if not reported thereby, as reported in another authoritative source) on the date of the Effective Time.

     

     

      

     

    PART I.

    INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS

     

    The documents containing the information specified in Part I of Form S-8 will be sent or given to participants in the 2017 Plan, as specified by Rule 428(b)(1) under the Securities Act of 1933, as amended (the “Securities Act”). Such documents need not be filed with the Securities and Exchange Commission (the “SEC”), either as part of the registration statement or as prospectuses or prospectus supplements pursuant to Rule 424 under the Securities Act. These documents and the documents incorporated by reference pursuant to Item 3 of Part II of this registration statement, taken together, constitute the prospectus required by Section 10(a) of the Securities Act.

     

     

      

     

    PART II.

    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

     

    Item 3. Incorporation of Documents by Reference.

     

    The following documents, which have been filed with the SEC by the Company, are incorporated by reference in this registration statement (in each case excluding any information deemed to have been furnished and not filed in accordance with SEC rules):

     

    (a)the Company’s Annual Report on Form 10-K for the year ended December 31, 2024, filed with the SEC on February 27, 2025 (the “2025 Annual Report”);

     

    (b)the portions of the Company’s Proxy Statement on Schedule 14A for its 2025 Annual Meeting of Shareholders, filed with the SEC on April 21, 2025, that are specifically incorporated by reference into the 2025 Annual Report;

     

    (c)the Company’s Quarterly Report on Form 10-Q for the quarters ended March 31, 2025, filed with the SEC on May 7, 2025; June 30, 2025, filed with the SEC on August 11, 2025; and September 30, 2025, filed with the SEC on October 28, 2025;

     

    (d)the Company’s Current Reports on Form 8-K, filed on April 29, 2025, May 14, 2025, May 21, 2025, June 4, 2025, June 20, 2025, July 24, 2025, and July 31, 2025; and

     

    (e)the description of the Company’s Common Stock set forth in Exhibit 4.5 to the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2019, and any other amendment or report filed for the purpose of updating such description.

     

    In addition, the Company incorporates by reference all documents filed by it pursuant to Section 13(a), 13(c), 14 or 15(d) of the Exchange Act (other than, in each case, documents or information therein deemed to have been furnished and not filed in accordance with SEC rules, unless specifically incorporated by reference into this registration statement) subsequent to the date hereof and prior to the filing of a post-effective amendment which indicates that all securities offered have been sold or which deregisters all securities then remaining unsold. All such incorporated documents shall be deemed to be a part of this registration statement from the dates of filing of such documents.

     

    Any statement contained herein or in a document incorporated by reference in this registration statement shall be deemed to be modified or superseded for purposes of this registration statement to the extent that a statement contained herein or in any other subsequently filed document which also is or is deemed to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or amended, to constitute a part of this registration statement.

     

    Item 4. Description of Securities.

     

    Not applicable.

     

    Item 5. Interests of Named Experts and Counsel.

     

    Faraz A. Choudhry, Deputy General Counsel and Assistant Corporate Secretary to the Board of Directors of the Company, has given an opinion of counsel with respect to the shares of the Company’s Common Stock to which this registration statement relates. Mr. Choudhry beneficially owns shares of the Company’s Common Stock and participates in various employee benefit plans of the Company, but is not eligible to participate in the 2017 Plan.

     

     

      

     

    Item 6. Indemnification of Directors and Officers.

     

    Delaware General Corporation Law. As a Delaware corporation, the Company is subject to the provisions of the General Corporation Law of the State of Delaware (the “Delaware General Corporation Law”).

     

    Section 145(a) of the Delaware General Corporation Law provides that a corporation may indemnify any person who was or is a party or is threatened to be made a party to any threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative or investigative (other than an action by or in the right of the corporation), by reason of the fact that the person is or was a director, officer, employee or agent of the corporation, or is or was serving at the request of the corporation as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise, against expenses (including attorneys’ fees), judgments, fines and amounts paid in settlement actually and reasonably incurred by the person in connection with such action, suit or proceeding if the person acted in good faith and in a manner the person reasonably believed to be in or not opposed to the best interests of the corporation, and, with respect to any criminal action or proceeding, had no reasonable cause to believe the person’s conduct was unlawful. The termination of any action, suit or proceeding by judgment, order, settlement, conviction or upon a plea of nolo contendere or its equivalent, shall not, of itself, create a presumption that the person did not act in good faith and in a manner which the person reasonably believed to be in or not opposed to the best interests of the corporation, and, with respect to any criminal action or proceeding, had reasonable cause to believe that the person’s conduct was unlawful.

     

    Section 145(b) of the Delaware General Corporation Law states that a corporation may indemnify any person who was or is a party or is threatened to be made a party to any threatened, pending or completed action or suit by or in the right of the corporation to procure a judgment in its favor by reason of the fact that the person is or was a director, officer, employee or agent of the corporation, or is or was serving at the request of the corporation as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise against expenses (including attorneys’ fees) actually and reasonably incurred by the person in connection with the defense or settlement of such action or suit if the person acted in good faith and in a manner the person reasonably believed to be in or not opposed to the best interests of the corporation and except that no indemnification shall be made in respect of any claim, issue or matter as to which such person shall have been adjudged to be liable to the corporation unless and only to the extent that the Delaware Court of Chancery or the court in which such action or suit was brought shall determine upon application that, despite the adjudication of liability but in view of all the circumstances of the case, such person is fairly and reasonably entitled to indemnity for such expenses as the Delaware Court of Chancery or such other court shall deem proper.

     

    Section 145(c) of the Delaware General Corporation Law provides that, to the extent that a present or former director or officer of a corporation has been successful on the merits or otherwise in defense of any action, suit or proceeding referred to in subsections (a) and (b) of Section 145, or in defense of any claim, issue or matter therein, such person shall be indemnified against expenses (including attorneys’ fees) actually and reasonably incurred by such person in connection therewith.

     

    Section 145(d) of the Delaware General Corporation Law states that any indemnification under subsections (a) and (b) of Section 145 (unless ordered by a court) shall be made by the corporation only as authorized in the specific case upon a determination that indemnification of the present or former director, officer, employee or agent is proper in the circumstances because the person has met the applicable standard of conduct set forth in subsections (a) and (b) of Section 145. Such determination shall be made with respect to a person who is a director or officer at

     

    the time of such determination (1) by a majority vote of the directors who are not parties to such action, suit or proceeding, even though less than a quorum, (2) by a committee of such directors designated by majority vote of such directors, even though less than a quorum, (3) if there are no such directors, or if such directors so direct, by independent legal counsel in a written opinion or (4) by the shareholders.

     

    Section 145(f) of the Delaware General Corporation Law states that the indemnification and advancement of expenses provided by, or granted pursuant to, the other subsections of Section 145 shall not be deemed exclusive of any other rights to which those seeking indemnification or advancement of expenses may be entitled under any bylaw, agreement, vote of shareholders or disinterested directors or otherwise, both as to action in such person’s official capacity and as to action in another capacity while holding such office.

     

    Section 145(g) of the Delaware General Corporation Law provides that a corporation shall have the power to purchase and maintain insurance on behalf of any person who is or was a director, officer, employee or agent of the corporation, or is or was serving at the request of the corporation as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise, against any liability asserted against such person and incurred by such person in any such capacity or arising out of such person’s status as such, whether or not the corporation would have the power to indemnify such person against such liability under the provisions of Section 145.

     

     

      

     

    Section 145(j) of the Delaware General Corporation Law states that the indemnification and advancement of expenses provided by, or granted pursuant to, Section 145 shall, unless otherwise provided when authorized or ratified, continue as to a person who has ceased to be a director, officer, employee or agent and shall inure to the benefit of the heirs, executors and administrators of such a person.

     

    Certificate of Incorporation. The Company’s Certificate of Incorporation provides that, to the fullest extent permissible under the Delaware General Corporation Law, the Company’s directors shall not be personally liable to the Company or its shareholders for monetary damages for breach of fiduciary duty as a director, except that a director shall be liable to the extent provided by applicable law (1) for breach of the director’s duty of loyalty to the Company or its shareholders, (2) for acts or omissions not in good faith or which involve intentional misconduct or a knowing violation of law, (3) pursuant to Section 174 of the Delaware General Corporation Law regarding the unlawful payment of dividends or stock redemptions or repurchases or (4) for any transaction from which the director derived an improper personal benefit.

     

    Bylaws. The Company’s Bylaws provide that the Company shall indemnify and hold harmless, to the fullest extent permitted by applicable law as it presently exists or may hereafter be amended, any person who was or is made or is threatened to be made a party or is otherwise involved in any threatened, pending, or completed action, suit or proceeding, whether civil, criminal, administrative or investigative, because he or she, or a person for whom he or she is the legal representative, is or was a director or officer of the Company or, while a director or officer of the Company, is or was serving at the request of the Company as a director, officer, employee or agent of another corporation, partnership, joint venture, trust, enterprise or nonprofit entity, including service with respect to employee benefit plans, against all liability and loss suffered and expenses (including attorneys’ fees) reasonably incurred by such person.

     

    The Company’s Bylaws provide that the Company shall advance to indemnified persons expenses incurred in defending any such proceedings, subject to an obligation to repay amounts so advanced if it shall ultimately be determined by final judicial decision from which there is no further right to appeal that such indemnified person is not entitled to be indemnified for such expenses under the Company’s Bylaws or otherwise.

     

    Indemnification Agreements. The Company has entered into an indemnification agreement with each of its directors and executive officers, which provides, among other things, that the Company will indemnify each such person to the fullest extent permitted by law, subject to certain conditions, against all expenses and certain other amounts actually and reasonably incurred by such person in connection with proceedings in which such person is involved, or is threatened to become involved, because such person is or was a director or officer of the Company, by reason of any action or inaction on the part of such person, or by reason of the fact that such person is or was serving at the request of the Company as a director, officer, trustee, partner, managing member, fiduciary, employee or agent of any other enterprise. The indemnification agreement also requires the Company, under certain circumstances, to advance expenses incurred by such person in connection with the investigation, defense, settlement or appeal of any such proceedings.

     

    Liability Insurance. The Company maintains directors’ and officers’ liability insurance which covers certain liabilities and expenses of the Company’s directors and officers and covers the Company for reimbursement of payments to the Company’s directors and officers in respect of such liabilities and expenses.

     

    Item 7. Exemption from Registration Claimed.

     

    Not applicable.

     

     

      

     

    Item 8. Exhibits.

     

    Number   Description
       
    4.1   Certificate of Incorporation of UnitedHealth Group Incorporated (incorporated by reference to Exhibit 3.1 to UnitedHealth Group Incorporated’s Registration Statement on Form 8-A/A Commission File No. 1-10864, filed on July 1, 2015).
       
    4.2   Amended and Restated Bylaws of UnitedHealth Group Incorporated, effective February 23, 2021 (incorporated by reference to Exhibit 3.2 to UnitedHealth Group Incorporated’s Current Report on Form 8-K, Commission File No. 1-10864, filed on February 26, 2021).
       
    4.3   Bind Benefits, Inc. 2017 Equity Incentive Plan, as amended
         
    5.1   Opinion of Faraz A. Choudhry, the Company’s Deputy General Counsel.
       
    23.1   Consent of Faraz A. Choudhry, the Company’s Deputy General Counsel (included in Exhibit 5.1).
       
    23.2   Consent of Deloitte & Touche LLP.
       
    24.1   Power of Attorney.
       
    107   Filing Fee Table.

     

     

      

     

    Item 9. Undertakings.

     

    (a) The undersigned registrant hereby undertakes:

     

    (1) To file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement:

     

    (i) To include any prospectus required by Section 10(a)(3) of the Securities Act;

     

    (ii) To reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the registration statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the SEC pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than a 20% change in the maximum aggregate offering price set forth in the “Calculation of Registration Fee” table in the effective registration statement; and

     

    (iii) To include any material information with respect to the plan of distribution not previously disclosed in the registration statement or any material change to such information in the registration statement;

     

    provided, however, that paragraphs (a)(1)(i) and (a)(1)(ii) above do not apply if the information required to be included in a post-effective amendment by those paragraphs is contained in reports filed with or furnished to the SEC by the registrant pursuant to Section 13 or Section 15(d) of the Exchange Act that are incorporated by reference in the registration statement.

     

    (2) That, for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

     

    (3) To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.

     

    (b) The undersigned registrant hereby undertakes that, for purposes of determining any liability under the Securities Act, each filing of the registrant’s annual report pursuant to Section 13(a) or Section 15(d) of the Exchange Act (and, where applicable, each filing of an employee benefit plan’s annual report pursuant to Section 15(d) of the Exchange Act) that is incorporated by reference in the registration statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

     

    (c) Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the SEC such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.

     

     

      

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Eden Prairie, State of Minnesota, on November 12, 2025.

     

      UNITEDHEALTH GROUP INCORPORATED
         
      By: /s/ Stephen J. Hemsley
        Stephen J. Hemsley
        Chief Executive Officer

     

    Pursuant to the requirements of the Securities Act of 1933, this registration statement has been signed by the following persons in the capacities indicated on November 12, 2025.

     

    Signature   Title
       

    /s/ Stephen J. Hemsley

     

    Chairman and Chief Executive Officer

    Stephen J. Hemsley   (principal executive officer)
       

    /s/ Wayne S. DeVeydt

     

    Chief Financial Officer

    Wayne S. DeVeydt   (principal financial officer)
       

    /s/ Thomas E. Roos

     

    Senior Vice President; Chief Accounting Officer

    Thomas E. Roos   (principal accounting officer)
         
    *   Director
    Charles D. Baker    
         
    *   Director
    Timothy P. Flynn    
         
    *   Director
    Paul R. Garcia    
         
    *   Director
    Kristen L. Gil    
         
    *   Director
    Michele J. Hooper    
         
    *   Director
    F. William McNabb III    
         
    *   Director
    Valerie C. Montgomery Rice, M.D.    
         
    *   Director
    John H. Noseworthy, M.D.    

     

    *The undersigned, by signing below, does hereby execute this registration statement on behalf of the directors of UnitedHealth Group Incorporated listed above pursuant to the Power of Attorney filed herewith as Exhibit 24.1.

     

      By: /s/ Faraz A. Choudhry
        Faraz A. Choudhry
        As Attorney-In-Fact

     

     

     

     

    Get the next $UNH alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $UNH

    DatePrice TargetRatingAnalyst
    10/29/2025$333.00Buy → Hold
    Deutsche Bank
    10/14/2025$406.00Buy
    Goldman
    7/31/2025$198.00Neutral → Underperform
    Robert W. Baird
    7/30/2025$400.00 → $325.00Outperform
    Oppenheimer
    6/11/2025$312.00Outperform → Neutral
    Robert W. Baird
    5/21/2025$270.00Hold → Reduce
    HSBC Securities
    5/19/2025$308.00Buy → Hold
    TD Cowen
    5/14/2025Strong Buy → Mkt Perform
    Raymond James
    More analyst ratings

    $UNH
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Garcia Paul R was granted 260 shares, increasing direct ownership by 9% to 3,021 units (SEC Form 4)

    4 - UNITEDHEALTH GROUP INC (0000731766) (Issuer)

    10/3/25 4:20:09 PM ET
    $UNH
    Medical Specialities
    Health Care

    Director Mcnabb Frederick William Iii was granted 289 shares, increasing direct ownership by 2% to 14,341 units (SEC Form 4)

    4 - UNITEDHEALTH GROUP INC (0000731766) (Issuer)

    10/3/25 4:19:59 PM ET
    $UNH
    Medical Specialities
    Health Care

    Director Gil Kristen was granted 162 shares, increasing direct ownership by 9% to 1,900 units (SEC Form 4)

    4 - UNITEDHEALTH GROUP INC (0000731766) (Issuer)

    10/3/25 4:19:44 PM ET
    $UNH
    Medical Specialities
    Health Care

    $UNH
    SEC Filings

    View All

    UnitedHealth Group Incorporated filed SEC Form 8-K: Leadership Update

    8-K - UNITEDHEALTH GROUP INC (0000731766) (Filer)

    11/21/25 5:20:04 PM ET
    $UNH
    Medical Specialities
    Health Care

    UnitedHealth Group Incorporated filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits

    8-K - UNITEDHEALTH GROUP INC (0000731766) (Filer)

    11/13/25 4:02:22 PM ET
    $UNH
    Medical Specialities
    Health Care

    SEC Form S-8 filed by UnitedHealth Group Incorporated

    S-8 - UNITEDHEALTH GROUP INC (0000731766) (Filer)

    11/13/25 6:07:17 AM ET
    $UNH
    Medical Specialities
    Health Care

    $UNH
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    UnitedHealth downgraded by Deutsche Bank with a new price target

    Deutsche Bank downgraded UnitedHealth from Buy to Hold and set a new price target of $333.00

    10/29/25 7:53:31 AM ET
    $UNH
    Medical Specialities
    Health Care

    Goldman initiated coverage on UnitedHealth with a new price target

    Goldman initiated coverage of UnitedHealth with a rating of Buy and set a new price target of $406.00

    10/14/25 8:54:29 AM ET
    $UNH
    Medical Specialities
    Health Care

    UnitedHealth downgraded by Robert W. Baird with a new price target

    Robert W. Baird downgraded UnitedHealth from Neutral to Underperform and set a new price target of $198.00

    7/31/25 7:58:50 AM ET
    $UNH
    Medical Specialities
    Health Care

    $UNH
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President & CFO Rex John F bought $4,999,919 worth of shares (17,175 units at $291.12), increasing direct ownership by 9% to 203,796 units (SEC Form 4)

    4 - UNITEDHEALTH GROUP INC (0000731766) (Issuer)

    5/16/25 6:11:47 PM ET
    $UNH
    Medical Specialities
    Health Care

    CEO, UHG Hemsley Stephen J bought $25,019,019 worth of shares (86,700 units at $288.57), increasing direct ownership by 15% to 679,493 units (SEC Form 4)

    4 - UNITEDHEALTH GROUP INC (0000731766) (Issuer)

    5/16/25 6:11:45 PM ET
    $UNH
    Medical Specialities
    Health Care

    Director Flynn Timothy Patrick bought $491,786 worth of shares (1,533 units at $320.80) (SEC Form 4)

    4 - UNITEDHEALTH GROUP INC (0000731766) (Issuer)

    5/16/25 12:28:22 PM ET
    $UNH
    Medical Specialities
    Health Care

    $UNH
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Scott Gottlieb, M.D., Joins UnitedHealth Group Board of Directors

    Dr. Scott Gottlieb, former U.S. Food and Drug Administration (FDA) commissioner, is joining UnitedHealth Group's (NYSE:UNH) Board of Directors, effective immediately. Dr. Gottlieb, 53, served as FDA commissioner from 2017 to 2019, where he became known for promoting transparency, strengthening patient safety and widening consumer choice. He led initiatives to modernize regulations to help foster medical innovation, promote competition in the pharmaceutical market, confront the opioid epidemic and curb youth tobacco use. "Scott has had an exceptional health care career in both the public and private sectors," said Stephen J. Hemsley, UnitedHealth Group's CEO and executive board chairman.

    11/18/25 6:45:00 AM ET
    $UNH
    Medical Specialities
    Health Care

    UnitedHealth Group Board Authorizes Payment of Quarterly Dividend

    The UnitedHealth Group (NYSE:UNH) board of directors has authorized payment of a cash dividend of $2.21 per share, to be paid on December 16, 2025, to all shareholders of record of UNH common stock as of the close of business December 8, 2025. About UnitedHealth Group UnitedHealth Group (NYSE:UNH) is a health care and well-being company with a mission to help people live healthier lives and help make the health system work better for everyone through two distinct and complementary businesses. Optum delivers care aided by technology and data, empowering people, partners and providers with the guidance and tools they need to achieve better health. UnitedHealthcare offers a full range of hea

    11/7/25 6:50:00 AM ET
    $UNH
    Medical Specialities
    Health Care

    UnitedHealth Group Reports Third Quarter 2025 Results and Raises Full Year 2025 Earnings Outlook

    Third Quarter 2025 Revenues of $113.2 Billion Grew 12% Year-Over-Year Third Quarter Earnings of $2.59 Per Share, Adjusted Earnings $2.92 Per Share Cash Flows from Operations were $5.9 Billion, or 2.3x Net Income Raises Full Year 2025 Earnings Outlook to at least $14.90 Per Share; Adjusted Earnings of at least $16.25 Per Share UnitedHealth Group (NYSE:UNH) reported third quarter 2025 results, reflecting the continued execution on its performance agenda, refocus on its mission and culture, and return to sustained growth. "We remain focused on strengthening performance and positioning for durable and accelerating growth in 2026 and beyond, and our results this quarter reflect so

    10/28/25 5:55:00 AM ET
    $UNH
    Medical Specialities
    Health Care

    $UNH
    Financials

    Live finance-specific insights

    View All

    UnitedHealth Group Board Authorizes Payment of Quarterly Dividend

    The UnitedHealth Group (NYSE:UNH) board of directors has authorized payment of a cash dividend of $2.21 per share, to be paid on December 16, 2025, to all shareholders of record of UNH common stock as of the close of business December 8, 2025. About UnitedHealth Group UnitedHealth Group (NYSE:UNH) is a health care and well-being company with a mission to help people live healthier lives and help make the health system work better for everyone through two distinct and complementary businesses. Optum delivers care aided by technology and data, empowering people, partners and providers with the guidance and tools they need to achieve better health. UnitedHealthcare offers a full range of hea

    11/7/25 6:50:00 AM ET
    $UNH
    Medical Specialities
    Health Care

    UnitedHealth Group Reports Third Quarter 2025 Results and Raises Full Year 2025 Earnings Outlook

    Third Quarter 2025 Revenues of $113.2 Billion Grew 12% Year-Over-Year Third Quarter Earnings of $2.59 Per Share, Adjusted Earnings $2.92 Per Share Cash Flows from Operations were $5.9 Billion, or 2.3x Net Income Raises Full Year 2025 Earnings Outlook to at least $14.90 Per Share; Adjusted Earnings of at least $16.25 Per Share UnitedHealth Group (NYSE:UNH) reported third quarter 2025 results, reflecting the continued execution on its performance agenda, refocus on its mission and culture, and return to sustained growth. "We remain focused on strengthening performance and positioning for durable and accelerating growth in 2026 and beyond, and our results this quarter reflect so

    10/28/25 5:55:00 AM ET
    $UNH
    Medical Specialities
    Health Care

    AM Best Downgrades Credit Ratings of UnitedHealth Group Incorporated and Its Subsidiaries; Revises Outlooks to Stable

    AM Best has downgraded the Long-Term Issuer Credit Ratings (Long-Term ICR) to "a-" (Excellent) from "a" (Excellent) and the Long and Short-Term Issue Credit Ratings (Long-Term IR; Short-Term IR) of UnitedHealth Group Incorporated (UnitedHealth Group) (Minnetonka, MN) (NYSE:UNH). Concurrently AM Best has downgraded the Financial Strength Rating (FSR) to A (Excellent) from A+ (Superior) and the Long-Term ICRs to "a+" (Excellent) from "aa-" (Superior) of the health and dental insurance subsidiaries of UnitedHealth Group, collectively referred to as UnitedHealthcare. The outlook of these Credit Ratings (ratings) has been revised to stable from negative. (See link below for a detailed listing of

    8/28/25 4:18:00 PM ET
    $UNH
    Medical Specialities
    Health Care

    $UNH
    Leadership Updates

    Live Leadership Updates

    View All

    Twilio Set to Join S&P MidCap 400

    NEW YORK, Aug. 14, 2025 /PRNewswire/ -- Twilio Inc. (NYSE:TWLO) will replace Amedisys Inc. (NASD: AMED) in the S&P MidCap 400 effective prior to the opening of trading on Tuesday, August 19. S&P 500 and S&P 100 constituent UnitedHealth Group Inc. (NYSE:UNH) acquired Amedisys in a deal completed today. Following is a summary of the changes that will take place prior to the open of trading on the effective date: Effective Date Index Name       Action Company Name Ticker GICS Sector August 19, 2025 S&P MidCap 400 Addition Twilio TWLO Information Technology August 19, 2025 S&P MidCap 400 Deletion Amedisys AMED Health Care For more information about S&P Dow Jones Indices, please visit www.spdji

    8/14/25 6:08:00 PM ET
    $AMED
    $SPGI
    $TWLO
    Medical/Nursing Services
    Health Care
    Finance: Consumer Services
    Finance

    UnitedHealth Group Investors: Please contact the Portnoy Law Firm to recover your losses. July 7, 2025 Deadline to file Lead Plaintiff Motion.

    Investors can contact the law firm at no cost to learn more about recovering their losses LOS ANGELES, May 13, 2025 (GLOBE NEWSWIRE) --  The Portnoy Law Firm advises UnitedHealth Group ("UnitedHealth" or the "Company") (NYSE:UNH) UnitedHealth investors have until July 7, 2025 to file a lead plaintiff motion. Investors are encouraged to contact attorney Lesley F. Portnoy, by phone 310-692-8883 or email: [email protected], to discuss their legal rights, or click here to join the case. The Portnoy Law Firm can provide a complimentary case evaluation and discuss investors' options for pursuing claims to recover their losses. UnitedHealth is a health insurance and health care services pr

    5/13/25 5:59:56 PM ET
    $UNH
    Medical Specialities
    Health Care

    Charlie Baker Joins UnitedHealth Group's Board of Directors

    UnitedHealth Group (NYSE:UNH) announced Charlie Baker, the former governor of Massachusetts and a prominent former health care executive, has been appointed to its Board of Directors, effective immediately. "Charlie Baker's leadership and deep health care experience will serve UnitedHealth Group well in its efforts to make the health system work better for everyone," said UnitedHealth Group Board Chairman Stephen J. Hemsley. "Charlie is an outstanding addition to our board given his proven track record in government and in leading businesses in the health sector, including care delivery and benefits." "UnitedHealth Group has unique capabilities to improve health care outcomes, lower cos

    11/3/23 4:00:00 PM ET
    $UNH
    Medical Specialities
    Health Care

    $UNH
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by UnitedHealth Group Incorporated (Amendment)

    SC 13G/A - UNITEDHEALTH GROUP INC (0000731766) (Subject)

    2/13/24 5:16:09 PM ET
    $UNH
    Medical Specialities
    Health Care

    SEC Form SC 13G/A filed by UnitedHealth Group Incorporated (Amendment)

    SC 13G/A - UNITEDHEALTH GROUP INC (0000731766) (Subject)

    2/9/24 10:05:20 AM ET
    $UNH
    Medical Specialities
    Health Care

    SEC Form SC 13G/A filed by UnitedHealth Group Incorporated (Amendment)

    SC 13G/A - UNITEDHEALTH GROUP INC (0000731766) (Subject)

    2/9/23 12:39:51 PM ET
    $UNH
    Medical Specialities
    Health Care